{
  "id": "8f9ddd1659e03189",
  "title": "Actinogen Medical Clears Interim DMC Review for XanaMIA Alzheimer Trial , Unveils AUD 12M Raise",
  "description": "20260202T231500Z",
  "content": "",
  "source": "tickerreport.com",
  "source_url": "https://www.tickerreport.com/banking-finance/13334008/actinogen-medical-clears-interim-dmc-review-for-xanamia-alzheimers-trial-unveils-aud-12m-raise.html",
  "published_at": "20260202T231500Z",
  "fetched_at": "2026-02-03T00:29:56.519436+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "ai"
  ],
  "location": "United States",
  "raw_data": {
    "url": "https://www.tickerreport.com/banking-finance/13334008/actinogen-medical-clears-interim-dmc-review-for-xanamia-alzheimers-trial-unveils-aud-12m-raise.html",
    "url_mobile": "",
    "title": "Actinogen Medical Clears Interim DMC Review for XanaMIA Alzheimer Trial , Unveils AUD 12M Raise",
    "seendate": "20260202T231500Z",
    "socialimage": "",
    "domain": "tickerreport.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}